Home / Beyond CBD / COVID medicines
BioPharm’s pharmaceutical manufacturing facility, while built for the patented process of CBD and other cannabinoid manufacture, has the flexibility to produce many other medicines and organic molecules. In emergency situations we can produce bulk anti-viral medicines locally.
At the outbreak of COVID pandemic, India, China and even United Kingdom began acting under laws preventing the export of certain critical medicines.
BioPharm have ability to source and manufacture certain critical medicines if required in response to COVID or future health pandemics.
Our COVID response R&D focus is on the development of trauma medicines.
Psilocybin mushrooms have been used by indigenous cultures for millennia for their therapeutic and mystical benefits. Western cultures have been denied this natural gift due to fear and taboo. Now, science has rediscovered its potential, and modern man is gaining access to this ancient tool.
Research is showing microdosing LSD (taking tiny amounts) to have powerful benefits, but the potential for overdose makes it unlikely to be allowed for public use. BioPharm have developed similar products with a ceiling level of effect to prevent overdose.
Ketamine is a popular surgical anaesthetic found to have mental health benefits, such as relief of treatment resistant depression, but is toxic to bladder. BioPharm team have worked on a number of improvements to this molecule.
MDMA is fast becoming a popular medicine for a variety of symptoms, but is toxic to heart and brain. BioPharm's EASE project has safer alternatives under development.
Stimulants such as cocaine and methamphetamine are widely used in the community but can have devastating consequences. Developing substitution drugs with less risk is becoming an attractive policy solution and we are working on the technology to get there.